Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec 27:4:489.
doi: 10.3389/fimmu.2013.00489.

Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Daniel Bertin  1 , Delphine Stephan  2 , Michel Khrestchatisky  2 , Sophie Desplat-Jégo  1
Affiliations
Review

Is TWEAK a Biomarker for Autoimmune/Chronic Inflammatory Diseases?

Daniel Bertin et al. Front Immunol. .

Abstract

The TWEAK/Fn14 pathway is now well-known for its involvement in the modulation of inflammation in various human autoimmune/chronic inflammatory diseases (AICID) including lupus, rheumatoid arthritis, and multiple sclerosis. A panel of data is now available concerning TWEAK expression in tissues or biological fluids of patients suffering from AICID, suggesting that it could be a promising biological marker in these diseases. Evidences from several teams support the hypothesis that blocking TWEAK/Fn14 pathway is an attractive new therapeutic lead in such diseases and clinical trials with anti-TWEAK-blocking antibodies are in progress. In this mini-review we discuss the potential use of TWEAK quantification in AICD management in routine practice and highlight the challenge of standardizing data collection to better estimate the clinical utility of such a biological parameter.

Keywords: TWEAK; auto-immunity; biomarker; disease monitoring; serum levels; urinary levels.

PubMed Disclaimer

References

    1. Cooper GS, Bynum MLK, Somers EC. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J Autoimmun (2009) 33(3–4):197–20710.1016/j.jaut.2009.09.008 - DOI - PMC - PubMed
    1. Burkly LC, Michaelson JS, Hahm K, Jakubowski A, Zheng TS. TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine (2007) 40(1):1–1610.1016/j.cyto.2007.09.007 - DOI - PubMed
    1. Wisniacki N, Amaravadi L, Galluppi GR, Zheng TS, Zhang R, Kong J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin Ther (2013) 35(8):1137–4910.1016/j.clinthera.2013.06.008 - DOI - PubMed
    1. ATLAS Anti-TWEAK in Lupus Nephritis Patients. Clinical Trials.gov; (2013). Available from: http://clinicaltrials.gov/ct2/show/NCT01499355?term=BIIB023&rank=3
    1. Schwartz N, Rubinstein T, Burkly LC, Collins CE, Blanco I, Su L, et al. Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study. Arthritis Res Ther (2009) 11(5):R143.10.1186/ar2816 - DOI - PMC - PubMed